To date, the US Food and Drug Administration (FDA) has approved two anti-BCMA CAR-T therapies, including Abecma (Idecabtagene vicleucel, ide-cel) and Carvyti (Ciltacabtagene autoleucel, cilta-cel), and China National Medical Products Administration (NMPA) has approved one anti-BCMA CAR-T therapy Fucaso (Equecabtagene autoleucel, CT103A) for the treatment of R/R MM. Here, TNFRSF17 is linked to Miyoshi myopathy.